Summary
Signal counts
Assets tracked: 4
Watchlist assets: 4
Registry stop assets: 0
Sponsor overview
Shanghai Henlius Biotech
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07459738 | https://clinicaltrials.gov/study/NCT07459751 | https://clinicaltrials.gov/study/NCT07106892 | https://clinicaltrials.gov/study/NCT06839066 | https://clinicaltrials.gov/study/NCT06848699 | https://clinicaltrials.gov/study/NCT07269782 | https://clinicaltrials.gov/study/NCT07253142 | https://clinicaltrials.gov/study/NCT06742892 | https://clinicaltrials.gov/study/NCT06857279 | https://clinicaltrials.gov/study/NCT06907615 | https://clinicaltrials.gov/study/NCT07487519
Assets
Linked programs
- HLX43: Operational Burden Signal (2/5)
- HLX43 Dose 1;: Operational Burden Signal (2/5)
- HLX43 DOSE 1 (2.0 mg/kg): Operational Burden Signal (2/5)
- HLX43 DOSE 1 IN ≥2L TNBC: Operational Burden Signal (2/5)